Cited by 44Dementia and Cognitive Impairment ResearchDiabetes, Cardiovascular Risks, and LipoproteinsMenopause: Health Impacts and Treatments

Fasting Insulin Levels and Cognitive Decline in Older Women without Diabetes

Open access
van Oijen, Marieke, Okereke, Olivia I., Kang, Jae Hee, Pollak, Michael N., Hu, Frank B., Hankinson, Susan E., Grodstein, Francine·2008·Neuroepidemiology

Abstract

Background: Type 2 diabetes has been associated with an increased risk of dementia. To assess possible independent effects of insulin, we investigated the relation of insulin levels to cognitive decline in nondiabetic women. Methods: Fasting plasma insulin levels were measured in mid-life in 1,416 nondiabetic Nurses’ Health Study participants, who also completed cognitive testing that began 10 years later (current age: 70–75 years). Over 4 years, 3 assessments of general cognition, verbal memory, category fluency and attention were administered. Primary outcomes were the Telephone Interview for Cognitive Status (TICS) performance, the global score (average of all tests) and verbal memory (average of verbal recall tests). Linear mixed-effects models were used to calculate the association between insulin and cognitive decline. Results: Higher insulin levels were associated with a faster decline on the TICS and verbal memory. For analysis, batch-specific quartiles of insulin levels were constructed. Compared to the lowest quartile, adjusted differences in the annual rates of decline (with 95% CI values in parentheses) for the second, third and fourth quartiles were: TICS, –0.06 (–0.16, 0.03), –0.14 (–0.24, –0.04), and –0.09 (–0.19, 0.01) points (p trend = 0.04); verbal memory, –0.01 (–0.04, 0.02), –0.05 (–0.08, –0.02), and –0.02 (–0.05, 0.01) units (p trend = 0.02). These associations remained after multivariable adjustment. Conclusions: Our study provides evidence for a potential role of higher fasting insulin levels in cognitive decline, possibly independent of diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000126909

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Even modest elevations in these biomarkers are associated with adverse outcomes, even when they do not meet accepted thresholds for clinical intervention.

    “It is important to note that even modest elevations in these biomarkers are associated with adverse outcomes, even when they do not meet accepted thresholds for clinical intervention.21,22”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
van Oijen, M., Okereke, O. I., Kang, J. H., Pollak, M. N., Hu, F. B., Hankinson, S. E., & Grodstein, F.
Affiliations
Brigham and Women's Hospital (US)
Venue
Neuroepidemiology
Publisher
S. Karger AG
Published
2008
Volume
30
Issue
3
Pages
174-179
ISSN
  • 0251-5350 (ISSN-L)
  • 1423-0208
OpenAlex
W2106615840
Cited by
44
References
23
Citations by year
2026: 1 · 2024: 2 · 2020: 2 · 2019: 4 · 2018: 5 · 2017: 3 · 2016: 1 · 2015: 1 · 2013: 2 · 2012: 6
FWCI
3.98
Type
journal article
Language
en
Open access
Locations
  • Neuroepidemiology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion)
Funders
  • Stichting de Drie Lichten
  • National Institutes of Health (5r01ca049449-18, CA-49449, CA 87969)
  • National Institute on Aging (R01 AG24215, AG24215, R01AG024215)
  • National Cancer Institute (CA-49449, CA-87969, P01CA087969, R01‐CA049449, U01CA049449)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
fasting insulin, cognitive decline, older women, non-diabetic women, verbal memory, dementia risk, type 2 diabetes, Nurses' Health Study, cognitive aging
MeSH terms
Adult, Aged, Aging, Cognition, Educational Status, Fasting, Female, Humans, Insulin, Longitudinal Studies, Memory, Middle Aged, Psychological Tests

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review